Gilead Sciences vs Revolution Medicines stock
Side by side in plain words: who keeps more of its sales, grows faster, costs less and owes less.
Gilead Sciences is more profitable, grows faster and is cheaper for its profits. Revolution Medicines has less debt.
Side by side
| Gilead Sciences | Revolution Medicines | |
|---|---|---|
| $208 billion | $37.3 billion | |
| 28.9% | -3,768.3% | |
| +3.6% | −10.5% | |
| 24.5× | No profit yet | |
| 1.3 years | Net cash | |
| 18.4% | -50.1% | |
| 2.3% | – |
How we compare
Four contests with the same rules as each stock page: profit kept from sales (higher wins), yearly sales growth across the last reports, up to five years (higher wins), price per unit of yearly profit (lower P/E wins; a company without profit loses) and debt in years of earnings (lower wins). A winner is only named when both companies have the number.
More comparisons: Gilead Sciences vs UnitedHealth · Gilead Sciences vs AbbVie · Gilead Sciences vs Amgen · Gilead Sciences vs Johnson & Johnson · Revolution Medicines vs Amgen